Items Tagged ‘non-small cell lung cancer’

June 5, 2018

Xalkori Receives FDA Breakthrough Therapy Designation for Treatment of Lung Cancer with MET Alterations

By

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Xalkori (crizotinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with MET exon 14 alterations with disease progression on or after platinum-based chemotherapy. The FDA’s Breakthrough Therapy designation is intended to expedite the development and review of a medicine […]

View full entry

Tags: crizotinib, Lung Cancer, Lung Cancer - Non-Small Cell, MET exon 14 alterations, News, non-small cell lung cancer, nsclc, treatment, xalkori


April 24, 2018

Alcensa Provides Longer Symptom Improvement than Xalkori in ALK-positive Lung Cancer

By

CancerConnect News: Alecensa (alectinib) provides longer symptom improvement than Xalkori (crizotinib) in ALK-positive non-small-cell lung cancer (NSCLC), according to results presented at the European Lung Cancer Congress in in Geneva, Switzerland.1 About ALK + NSCLC Lung cancer is the leading cause of cancer death in the U.S. and around the world, highlighting the importance of […]

View full entry

Tags: Alcensa, Alecensa, alk-positive, Lung Cancer, Lung Cancer - Non-Small Cell, non-small cell lung cancer, xalkori


April 11, 2018

Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer

By

Younger patients with non-small cell lung cancer (NSCLC) are more likely to receive treatment than older patients, regardless of overall health and prognosis, according to the results of a study published in the Journal of Clinical Oncology. Lung cancer remains the leading cause of cancer death in the United States. Non–small cell lung cancer (NSCLC) […]

View full entry

Tags: impact of age on treatment, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer


January 24, 2018

FDA Broadens Gilotrif Indication to Previously Untreated, Metastatic NSCLC with Other Non-Resistant EGFR Mutations

By

CancerConnect News: The Food and Drug Administration (FDA) has granted approval to Gilotrif®  (afatinib) for a broadened indication in first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test. Lung cancer remains the leading cause of cancer death […]

View full entry

Tags: afatinib, EGFR, gilotrif, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, Precision Cancer Medicine


January 17, 2018

Keytruda in Combination with Alimta and Platinum Chemotherapy Improves Survival in Non Small Cell Lung Cancer

By

CancerConnect News: Keytruda (pembrolizumab) is the first PD1 Inhibitor to demonstrate improved overall survival when combined with chemotherapy as primary treatment for metastatic non-squamous non-small cell lung cancer (NSCLC). The KEYNOTE-189 clinical trial evaluated Keytruda in combination with Alimta (pemetrexed) and cisplatin or carboplatin chemotherapy for the first-line treatment of patients with NSCLC. Interim results […]

View full entry

Tags: checkpoint inhibitor, immunotherapy, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, non-squamous, nsclc, PD1 Inhibitor, pembrolizumab, Precision Cancer Medicine


January 15, 2018

Tagrisso Improves Progression-free Survival in Asian EGFR-mutated Lung Cancer Patients

By

CancerConnect News: Tagrisso (osimertinib) improves progression-free survival compared to standard first line therapy in Asian patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). 1,2 Lung cancer is the number one cause of cancer-related deaths in the United States.  Research identifying specific molecular and genetic components of a patient’s cancer cells has led to […]

View full entry

Tags: EGFR-TKI, first-line treatment, Lung Cancer, News, non-small cell lung cancer, nsclc, osmertinib, tagrisso


January 8, 2018

First Line Combination Therapy Improves Progression-Free Survival In Advanced Lung Cancer

By

A recently reported study confirms that combination therapy using the “checkpoint inhibitor” Tecentriq® (atezolizumab) and chemotherapy as first line treatment for advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of the phase III IMpower150 trial.1 About Lung Cancer Lung cancer remains the leading cause of cancer-related deaths worldwide. In the […]

View full entry

Tags: checkpoint inhibitors, immunotherapy, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, nivolumab, non-small cell lung cancer, opdivo, pembrolizumab, Precision Cancer Medicine, Tecentriq


December 6, 2017

The Role of Immunotherapy in the Treatment of Advanced Non Small Cell Lung Cancer

By

Treatment options for advanced NSCLC fit into 3 main categories… Targeted Therapy – we test lung cancer for specific mutations to see if we have an appropriate targeted medication. Immunotherapy – if targeted therapy is not an option immunotherapy should be part of the initial treatment strategy. We test the cancer for a specific protein […]

View full entry

Tags: keytruda, lung biomarker, Lung Cancer, Lung Cancer - Non-Small Cell, lung cancer treatment, News, non-small cell lung cancer, Precision Cancer Medicine


November 13, 2017

Alcensa Precision Medicine Approved for (ALK) Positive Non-Small Cell Lung Cancer

By

The Food and Drug Administration granted regular approval to Alcensa (alectinib), for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. In December 2015, Alcensa received accelerated approval for treatment of patients with ALK-positive metastatic NSCLC whose disease progressed on or who were intolerant […]

View full entry

Tags: Alcensa, alectinib, alk, anaplastic lymphoma kinase, crizotinib, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, positive metastatic, Precision Cancer Medicine, xalkori


October 23, 2017

Keytruda® Significantly Prolongs Survival Compared to Chemotherapy First-Line Treatment for Advanced Non-Small Cell Lung Cancer

By

Updated study results presented at the World Congress on Lung Cancer this week continue to demonstrate that treatment of advanced non small cell lung cancer (NSCLC) whose tumors expressed high levels of PD-1 with Keytruda® (pembrolizumab) is superior to standard chemotherapy and significantly improves survival. Lung cancer remains the leading cause of cancer-related deaths worldwide. In […]

View full entry

Tags: immunotherapy, keytruda, News, Non-Hodgkin's Lymphoma, non-small cell lung cancer, opdivo, PD-1, Precision Cancer Medicine


March 16, 2015

Zykadia™

By

Class: Biological Therapy Generic Name: ceritinib Trade Name: Zykadia™   For which conditions is this drug approved? Zykadia is approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) that is caused by a defect in a gene called ALK (anaplastic lymphoma kinase) whose disease has worsened after taking Xalkori® (crizotinib) or cannot […]

View full entry

Tags: Biological Therapy, Drug Dictionary, non-small cell lung cancer, Z


March 16, 2015

ceritinib

By

Class: Biological Therapy Generic Name: ceritinib Trade Name: Zykadia™ For which conditions is this drug approved? Zykadia is approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) that is caused by a defect in a gene called ALK (anaplastic lymphoma kinase) whose disease has worsened after taking Xalkori® (crizotinib) or cannot tolerate […]

View full entry

Tags: Biological Therapy, C, Drug Dictionary, non-small cell lung cancer